The NeurologyLive® Narcolepsy Disease Spotlight page offers specific updates and coverage on the latest expert conversations and data readouts related to the treatment and management of patients with the sleep disorder.
May 13th 2025
A recent interim analysis of a 5-year observational study showed sustained benefit of pitolisant in reducing excessive daytime sleepiness and cataplexy in patients with narcolepsy.
Harmony Begins New Phase 3 TEMPO Study of Wake-Promoting Therapy Pitolisant in Prader-Willi Syndrome
April 9th 2024The newly initiated phase 3 trial follows a successful phase 2 study where treatment with pitolisant resulted in greater improvement on the Epworth Sleepiness Scale for Children and Adolescents than placebo.
Prioritizing Sleep Health in the Modern World of Sleep Disorders: Ana Krieger, MD, MPH
April 1st 2024The medical director of the Center for Sleep Medicine at Weill Cornell Medicine talked about the importance of sleep health in modern life with the increasing prevalence of sleep disorders such as narcolepsy in the United States. [WATCH TIME: 5 minutes]
Changing the Perception of Narcolepsy to Reduce Stigma: Mark I. Boulos, MD, MSc, FRCP, CSCN
January 11th 2024The associate professor, department of medicine, division of neurology, Institute of Medical Science, University of Toronto, discussed recent research that challenged the conventional definitions of sleep and how narcolepsy is often stigmatized. [WATCH TIME: 2 minutes]
Once-Nightly Sodium Oxybate Effective in Both Narcolepsy Type 1 and 2
December 16th 2023Subgroups of narcolepsy types 1 and 2 had significant reductions in a number of secondary outcomes, including number of sleep stage transitions, number of nocturnal arousals, and improvements in sleep quality.
Evaluating Positive Phase 1 Trial Data for Narcolepsy Agent ALKS 2680
November 11th 2023Brendon Yee, PhD, a respiratory and sleep physician at the Woolcock Institute of Medical Research, discussed findings from a recent phase 1 trial presented at World Sleep Congress 2023 in which ALKS 2680 demonstrated improvements in wakefulness among patients with narcolepsy type 1.